Venezuela to examine all pharma patents?

3 December 2009

'Patents as element of exclusion and limit to the health of the town,' was the subject of a lecture in Venezuela, which saw the head of different institutions united, according to a posting on the IP Tango web site. Last week, the Venezuelan Minister of Commerce, Eduardo Saman, the Servicio Autonomo de la Propiedad Intelectual (SAPI)'s director Arlen Pinate and the Camara de Medicamentos y Afines' (CANAMEGA) president Jorge Rivas, declared their views regarding pharmaceutical patents.

Eduardo Saman said that 'all pharmaceutical patents are to be examined to see if they have fulfilled the corresponding proceeding.' To this, Mr Rivas added that the SAPI needs to scrutinize all pharmaceutical patents that have been granted under Andean Community Decision 311, 313, and 344.

The situation comes after two Bayer's pharmaceutical patents were annulled by the government (The Pharma Letter November 30). As reported early in the IP Tango blog, the procedures under which these two patents were annulled caused controversy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK